PREVALENCE OF MALNUTRITION ASSESSED BY PG-SGA AND ASSOCIATION WITH SKELETAL MUSCLE INDEX IN CANCER PATIENTS AT TREATMENT INITIATION
Main Article Content
Abstract
Aims: To determine the prevalence of malnutrition using the PG-SGA and to explore related factors in cancer patients at treatment initiation, emphasizing the role of skeletal muscle index (SMI).
Methods: This cross-sectional study involved 152 cancer patients beginning treatment. Nutritional assessment was performed using PG-SGA. Bioelectrical impedance analysis (BIA) was used to measure body composition, including intracellular water (ICW), extracellular water (ECW), protein mass, fat mass, and SMI. Correlation and multivariate linear regression analysis were performed on factors related to PG-SGA scores.
Results: The prevalence of malnutrition by PG-SGA was 54.6% (83/152), and the prevalence of low SMI was 38.2%. The malnourished group had significantly lower ICW, ECW, protein mass and SMI than the non-malnourished group. PG-SGA score was negatively correlated with SMI (ρ = −0.236; p = 0.003). In multivariable linear regression, SMI (b = −1.078; p = 0.004), albumin (b=−0,187; p=0,043), and platelet count (b=−0,009; p=0,049) were negatively associated with PG-SGA score.
Conclusion: Among cancer patients at treatment initiation, malnutrition is common, and SMI is associated with malnutrition severity.
Keywords
PG-SGA, malnutrition, cancer, skeletal muscle index.
Article Details
References
2. Hébuterne X, Lemarié E, Michallet M, de Montreuil CB, Schneider SM, Goldwasser F. Prevalence of malnutrition and current use of nutrition support in patients with cancer. JPEN J Parenter Enteral Nutr. 2014 Feb;38(2):196-204. doi:10.1177/0148607113502674.
3. Muscaritoli M, Arends J, Bachmann P, Baracos V, Barthelemy N,et al. ESPEN practical guideline: Clinical Nutrition in cancer. Clin Nutr. 2021 May;40(5):2898-913. doi:10.1016/j.clnu.2021.02.005.
4. Cederholm T, Jensen GL, Correia M, Gonzalez MC, Fukushima R, Higashiguchi T, et al. GLIM criteria for the diagnosis of malnutrition - A consensus report from the global clinical nutrition community. Clin Nutr. 2019 Feb;38(1):1-9. doi: 10.1016/j.clnu.2018.08.002.
5. Branco MG, Mateus C, Capelas ML, Pimenta N, Santos T, Makitie A, et al. Bioelectrical Impedance Analysis (BIA) for the Assessment of Body Composition in Oncology: A Scoping Review. Nutrients. 2023 Nov 15;15(22):4792. doi: 10.3390/nu15224792.
6. Chen LK, Woo J, Assantachai P, Auyeung TW, Chou MY, Iijima K, et al. Asian Working Group for Sarcopenia: 2019 Consensus Update on Sarcopenia Diagnosis and Treatment. J Am Med Dir Assoc. 2020 Mar;21(3):300-307.e2. doi: 10.1016/j.jamda.2019.12.012.
7. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982 Dec;5(6):649-55.
8. Bauer J, Capra S, Ferguson M. Use of the scored Patient-Generated Subjective Global Assessment (PG-SGA) as a nutrition assessment tool in patients with cancer. Eur J Clin Nutr. 2002 Aug;56(8):779-85. doi: 10.1038/sj.ejcn.1601412.
9. Hong X, Cui B, Wang M, Yang Z, Wang L, Xu Q. Systemic Immune-inflammation Index, Based on Platelet Counts and Neutrophil-Lymphocyte Ratio, Is Useful for Predicting Prognosis in Small Cell Lung Cancer. Tohoku J Exp Med. 2015 Aug;236(4):297-304. doi: 10.1620/tjem.236.297.
10. Yildiz A, Yigit A, Benli AR. The Impact of Nutritional Status and Complete Blood Count Parameters on Clinical Outcome in Geriatric Critically Ill Patients. J Clin Med Res. 2018 Jun;10(7):588-92. doi: 10.14740/jocmr3461w.
11. Kubota K, Ito R, Narita N, Tanaka Y, Furudate K, Akiyama N, et al. Utility of prognostic nutritional index and systemic immune-inflammation index in oral cancer treatment. BMC Cancer. 2022 Apr 7;22(1):368. doi: 10.1186/s12885-022-09439-x.
12. Farag CM, Antar R, Akosman S, Ng M, Whalen MJ. What is hemoglobin, albumin, lymphocyte, platelet (HALP) score? A comprehensive literature review of HALP's prognostic ability in different cancer types. Oncotarget. 2023 Feb 25:14:153-172. doi: 10.18632/oncotarget.28367.